Related references
Note: Only part of the references are listed.Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review
Lucas Guillo et al.
JOURNAL OF CROHNS & COLITIS (2021)
Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature
Mohamed Attauabi et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2021)
Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease
Uma Mahadevan et al.
GASTROENTEROLOGY (2021)
Effect of Ustekinumab on Extraintestinal Diseases in Refractory Crohn's Disease
Antonio Tursi et al.
JOURNAL OF CROHNS & COLITIS (2021)
Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients
Nicolae-Catalin Mechie et al.
MEDICINE (2021)
A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects
Lei Gao et al.
FRONTIERS IN PHARMACOLOGY (2021)
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
Anthony Buisson et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)
Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study
Yanna Ko et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease
Siddharth Singh et al.
GASTROENTEROLOGY (2021)
The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
Neeraj Narula et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)
Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study
Ahmad Albshesh et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn's Disease: The SEAVUE study
P. M. Irving et al.
JOURNAL OF CROHNS & COLITIS (2021)
Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease
Michael T. Dolinger et al.
INFLAMMATORY BOWEL DISEASES (2021)
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy
Luc Manlay et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
Joana Torres et al.
JOURNAL OF CROHNS & COLITIS (2020)
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease
Edward Yang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment
Vince B. C. Biemans et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series
Frank M. Phillips et al.
JOURNAL OF CROHNS & COLITIS (2020)
Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach
Ferdinando D'Amico et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2020)
Crohn's disease
Giulia Roda et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID
Constance Chapuis-Biron et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review
Thomas Chateau et al.
JOURNAL OF CROHNS & COLITIS (2019)
Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naive Patients
Elmar R. Aliyev et al.
PHARMACOTHERAPY (2019)
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2018)
Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
Przemyslaw Holko et al.
PHARMACOECONOMICS (2018)
FISTULA HEALING IN PIVOTAL STUDIES OF USTEKINUMAB IN CROHN'S DISEASE
Bruce E. Sands et al.
GASTROENTEROLOGY (2017)
Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy
Julian Panes et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease
Robert Battat et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
Geoffrey C. Nguyen et al.
GASTROENTEROLOGY (2016)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease
C. J. van der Woude et al.
JOURNAL OF CROHNS & COLITIS (2015)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The use of ustekinumab in autoimmune disease
Caitriona Ryan et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William J. Sandborn et al.
GASTROENTEROLOGY (2008)
Share Paper
